Literature DB >> 21310193

Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.

Jonelle Mattiacio1, Scott Walter, Matt Brewer, William Domm, Alan E Friedman, Stephen Dewhurst.   

Abstract

The generation of strong, virus-neutralizing antibody responses to the HIV-1 envelope spike (Env) is a major goal in HIV-1 vaccine research. To try to enhance the Env-specific response, we displayed oligomeric gp140 on a virus-like scaffold provided by the lambda phage capsid. To do this, an in vitro complementation system was used to "decorate" phage particles with glycosylated, mammalian cell-derived envelope oligomers. We compared the immune response to lambda phage particles displaying HIV-1 Env to that elicited by soluble oligomeric gp140 in rabbits. Env-binding antibody titers were higher in animals that received oligomeric gp140 as compared to Env decorated phage particles, as were virus neutralizing antibody responses. The Env decorated phage particles were, however, able to efficiently boost a protein-primed humoral response to levels equivalent to those elicited by high-dose adjuvanted Env oligomers. These results show that display of HIV-1 envelope spikes on the bacteriophage lambda capsid does not result in an improved, Env-specific humoral immune response.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310193      PMCID: PMC3062207          DOI: 10.1016/j.vaccine.2011.01.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  54 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics.

Authors:  E Santi; S Capone; C Mennuni; A Lahm; A Tramontano; A Luzzago; A Nicosia
Journal:  J Mol Biol       Date:  2000-02-18       Impact factor: 5.469

Review 4.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Novel fold and capsid-binding properties of the lambda-phage display platform protein gpD.

Authors:  F Yang; P Forrer; Z Dauter; J F Conway; N Cheng; M E Cerritelli; A C Steven; A Plückthun; A Wlodawer
Journal:  Nat Struct Biol       Date:  2000-03

6.  Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  X Yang; M Farzan; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Authors:  T G Evans; W Bonnez; R C Rose; S Koenig; L Demeter; J A Suzich; D O'Brien; M Campbell; W I White; J Balsley; R C Reichman
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

8.  Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization.

Authors:  I Fogelman; V Davey; H D Ochs; M Elashoff; M B Feinberg; J Mican; J P Siegel; M Sneller; H C Lane
Journal:  J Infect Dis       Date:  2000-07-21       Impact factor: 5.226

9.  Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes.

Authors:  Lakshman N A Gamage; John Ellis; Sidney Hayes
Journal:  Vaccine       Date:  2009-08-25       Impact factor: 3.641

10.  A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis.

Authors:  Gunther Spohn; Reto Guler; Pål Johansen; Iris Keller; Muazzam Jacobs; Markus Beck; Franziska Rohner; Monika Bauer; Klaus Dietmeier; Thomas M Kündig; Gary T Jennings; Frank Brombacher; Martin F Bachmann
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

View more
  11 in total

Review 1.  Bacteriophage lambda: Early pioneer and still relevant.

Authors:  Sherwood R Casjens; Roger W Hendrix
Journal:  Virology       Date:  2015-03-03       Impact factor: 3.616

2.  Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Authors:  J Pablo Jaworski; James Kobie; Zachary Brower; Delphine C Malherbe; Gary Landucci; William F Sutton; Biwei Guo; Jason S Reed; Enrique J Leon; Flora Engelmann; Bo Zheng; Al Legasse; Byung Park; Mary Dickerson; Anne D Lewis; Lois M A Colgin; Michael Axthelm; Ilhem Messaoudi; Jonah B Sacha; Dennis R Burton; Donald N Forthal; Ann J Hessell; Nancy L Haigwood
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

3.  Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

Authors:  William Domm; Lauren Brooks; Hung Li Chung; Changyong Feng; William J Bowers; Gene Watson; James L McGrath; Stephen Dewhurst
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

4.  Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies.

Authors:  William Domm; Matthew Brewer; Steven F Baker; Changyong Feng; Luis Martínez-Sobrido; John Treanor; Stephen Dewhurst
Journal:  J Virol Methods       Date:  2013-12-06       Impact factor: 2.014

5.  Nanoparticles decorated with viral antigens are more immunogenic at low surface density.

Authors:  Matthew G Brewer; Anthony DiPiazza; Joshua Acklin; Changyong Feng; Andrea J Sant; Stephen Dewhurst
Journal:  Vaccine       Date:  2017-01-03       Impact factor: 3.641

6.  Anti-idiotypic monobodies derived from a fibronectin scaffold.

Authors:  Mark A Sullivan; Lauren R Brooks; Philip Weidenborner; William Domm; Jonelle Mattiacio; Qingfu Xu; Michael Tiberio; Timothy Wentworth; James Kobie; Peter Bryk; Bo Zheng; Mary Murphy; Ignacio Sanz; Stephen Dewhurst
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

7.  Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5.

Authors:  Jharon Silva; Oksana Polesskaya; Walter Knight; Johnny Ting Zheng; Megan Granger; Tenée Lopez; Fernando Ontiveros; Changyong Feng; Chen Yan; Karl A Kasischke; Stephen Dewhurst
Journal:  J Neuroinflammation       Date:  2012-11-20       Impact factor: 8.322

Review 8.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

9.  9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.

Authors:  James J Kobie; Danielle C Alcena; Bo Zheng; Peter Bryk; Jonelle L Mattiacio; Matthew Brewer; Celia Labranche; Faith M Young; Stephen Dewhurst; David C Montefiori; Alexander F Rosenberg; Changyong Feng; Xia Jin; Michael C Keefer; Ignacio Sanz
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

10.  9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.

Authors:  Danielle C Alcéna; James J Kobie; Denise A Kaminski; Alexander F Rosenberg; Jonelle L Mattiacio; Matthew Brewer; Stephen Dewhurst; Carrie Dykes; Xia Jin; Michael C Keefer; Ignacio Sanz
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.